ADMA Biologics Announces Preliminary Full Year 2025 Unaudited Total Revenue and Provides Business Update

FY 2025 Preliminary Unaudited Total Revenue of Approximately $510–511 Million Meets or Exceeds Prior Guidance Previously Provided FY 2025 Adjusted EBITDA (1) and Adjusted Net Income (2) Guidance Reiterated Year-End 2025 Cash Grew to Approximately $88 Million with an Unaudited Operating Cash Flow